{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:34:33Z","timestamp":1770489273609,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Apocrine carcinoma is a rare tumor that constitutes &lt; 4% of all breast malignancies, characterized by the proliferation of large atypical cells with strictly defined borders, abundant eosinophilic cytoplasm, large nuclei, and prominent nucleoli in more than 90% of tumor cells. Triple-negative apocrine carcinoma is a rare molecular subtype that constitutes less than 1% of triple-negative breast cancers and is characterized by negative expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor, with positive expression of androgen receptor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a case of a 45-year-old Syrian female who presented to our hospital due to a painless palpable mass in her left breast. Following physical and radiological examinations, an excisional biopsy was performed. Microscopic examination of the specimen followed by immunohistochemical staining revealed the diagnosis of a triple-negative apocrine carcinoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Triple-negative apocrine carcinoma is an extremely rare neoplasm that must be considered in the differential diagnoses of breast lesions through detailed clinical, histological, and immunohistochemical correlations. In our manuscript, we aimed to present the first case report of a Syrian female who was diagnosed with a triple-negative apocrine carcinoma, aiming to highlight the importance of detailed clinical, histological and immunohistochemical correlations with a detailed review of diagnostic criteria, molecular characteristics, and treatment recommendations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-021-01539-3","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T12:03:08Z","timestamp":1637841788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-1598","authenticated-orcid":false,"given":"Sawsan","family":"Ismail","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidara","family":"Kherbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Skef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadim","family":"Zahlouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafik","family":"Abdulal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuheir","family":"Alshehabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"1539_CR1","first-page":"1393","volume":"28","author":"S Vranic","year":"2013","unstructured":"Vranic S, Schmitt F, Sapino A, et al. Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol. 2013;28:1393\u2013409.","journal-title":"Histol Histopathol"},{"issue":"5","key":"1539_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/modpathol.2010.50","volume":"23","author":"S Vranic","year":"2010","unstructured":"Vranic S, Tawfik O, Palazzo J, et al. EGFR and HER-2\/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol. 2010;23(5):644\u201353. https:\/\/doi.org\/10.1038\/modpathol.2010.50.","journal-title":"Mod Pathol"},{"key":"1539_CR3","doi-asserted-by":"publisher","unstructured":"Liao HY, Zhang WW, Sun JY, et al. The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer. 2018;9(2):296\u2013303. Published 2018 Jan 1. doi:https:\/\/doi.org\/10.7150\/jca.22280","DOI":"10.7150\/jca.22280"},{"issue":"6","key":"1539_CR4","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/jso.26129","volume":"122","author":"CA Arciero","year":"2020","unstructured":"Arciero CA, Diehl AH 3rd, Liu Y, et al. Triple-negative apocrine carcinoma: a rare pathologic subtype with a better prognosis than other triple-negative breast cancers. J Surg Oncol. 2020;122(6):1232\u20139. https:\/\/doi.org\/10.1002\/jso.26129.","journal-title":"J Surg Oncol"},{"key":"1539_CR5","first-page":"403","volume":"62","author":"E Krompecher","year":"1916","unstructured":"Krompecher E. Zur histogene und morphologie der cystenmamma (maldie kystique reclus, cystadenoma schimmelbuscin, mastitis chronica cystic konig) des intrakanaliken kystadenomas und der kystadenokarzinome der brustdruse (hidrokystoma, kystoadenoma, hidrokystadenocarzinoma mammae). Beitr Pathol Anat. 1916;62:403\u201310.","journal-title":"Beitr Pathol Anat"},{"key":"1539_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.breast.2004.06.003","volume":"14","author":"H Japaze","year":"2005","unstructured":"Japaze H, Emina J, Diaz C, et al. \u2018Pure\u2019 invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast. 2005;14:3\u201310.","journal-title":"Breast"},{"key":"1539_CR7","doi-asserted-by":"crossref","unstructured":"Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma-rare types; review of the literature. Ann Oncol 2009;20:1763e70.","DOI":"10.1093\/annonc\/mdp245"},{"key":"1539_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF02967076","volume":"4","author":"S Onoue","year":"1997","unstructured":"Onoue S, Katoh T, Chigira H, et al. A case of apocrine carcinoma of the breast presenting as two cysts. Breast Cancer. 1997;4:193\u20136.","journal-title":"Breast Cancer"},{"key":"1539_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejrex.2006.08.004","volume":"60","author":"G Gokalp","year":"2006","unstructured":"Gokalp G, Topal U, Haholu A, et al. Apocrine carcinoma of the breast: mammography and ultrasound findings. Eur J Radiol Extra. 2006;60:55\u20139.","journal-title":"Eur J Radiol Extra"},{"issue":"5","key":"1539_CR10","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3348\/kjr.2015.16.5.1006","volume":"16","author":"KJ Seo","year":"2015","unstructured":"Seo KJ, An YY, Whang IY, et al. Sonography of Invasive Apocrine Carcinoma of the Breast in Five Cases. Korean J Radiol. 2015;16(5):1006\u201311. https:\/\/doi.org\/10.3348\/kjr.2015.16.5.1006.","journal-title":"Korean J Radiol"},{"key":"1539_CR11","doi-asserted-by":"publisher","unstructured":"Min Kim J, Young Kim S, Hye Oh M, et al. A rare case of invasive apocrine carcinoma of the breast with unusual radiologic findings. Iran J Radiol. 2016;13(3):e35298. Published 2016 May 31. doi:https:\/\/doi.org\/10.5812\/iranjradiol.35298","DOI":"10.5812\/iranjradiol.35298"},{"key":"1539_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/modpathol.2009.159","volume":"23","author":"LA Niemeier","year":"2010","unstructured":"Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23:205\u201312.","journal-title":"Mod Pathol"},{"key":"1539_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1524-4741.1996.tb00107.x","volume":"2","author":"FA Tavassoli","year":"1996","unstructured":"Tavassoli FA, Purcell CA, Bratthauer GL, et al. Androgen receptor expression along with loss of Bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications of therapy. Breast J. 1996;2:261\u20139.","journal-title":"Breast J"},{"key":"1539_CR14","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1038\/sj.onc.1208561","volume":"24","author":"P Farmer","year":"2005","unstructured":"Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660\u201371.","journal-title":"Oncogene"},{"key":"1539_CR15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1593\/neo.08274","volume":"10","author":"A Naderi","year":"2008","unstructured":"Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia. 2008;10:542\u20138.","journal-title":"Neoplasia"},{"key":"1539_CR16","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/bcr3232","volume":"14","author":"A Naderi","year":"2012","unstructured":"Naderi A, Meyer M. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Res. 2012;14:R111.","journal-title":"Breast Cancer Res"},{"issue":"12","key":"1539_CR17","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41379-020-0589-x","volume":"33","author":"X Sun","year":"2020","unstructured":"Sun X, Zuo K, Yao Q, et al. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Mod Pathol. 2020;33(12):2473\u201382. https:\/\/doi.org\/10.1038\/s41379-020-0589-x.","journal-title":"Mod Pathol"},{"issue":"18","key":"1539_CR18","doi-asserted-by":"publisher","first-page":"7523","DOI":"10.1002\/cam4.2634","volume":"8","author":"W Wu","year":"2019","unstructured":"Wu W, Wu M, Peng G, et al. Prognosis in triple-negative apocrine carcinomas of the breast: a population-based study. Cancer Med. 2019;8(18):7523\u201331. https:\/\/doi.org\/10.1002\/cam4.2634.","journal-title":"Cancer Med"},{"key":"1539_CR19","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1016\/j.clbc.2018.02.012","volume":"18","author":"I Meattini","year":"2018","unstructured":"Meattini I, Pezzulla D, Saieva C, et al. Triple negative apocrine carcinomas as a distinct subtype of triple negative breast cancer: a casecontrol study. Clin Breast Cancer. 2018;18:e773\u201380. https:\/\/doi.org\/10.1016\/j.clbc.2018.02.012.","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"1539_CR20","doi-asserted-by":"publisher","first-page":"T183","DOI":"10.1530\/ERC-14-0248","volume":"21","author":"GA Tarulli","year":"2014","unstructured":"Tarulli GA, Butler LM, Tilley WD, et al. Bringing androgens up a NOTCH in breast cancer. Endocr Relat Cancer. 2014;21(4):T183-202.","journal-title":"Endocr Relat Cancer"},{"issue":"19","key":"1539_CR21","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","volume":"19","author":"A Gucalp","year":"2013","unstructured":"Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505\u201312.","journal-title":"Clin Cancer Res"},{"key":"1539_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-014-0406-x","volume":"16","author":"BDBJA Lehmann","year":"2014","unstructured":"Lehmann BDBJA, Schafer JM, Pendleton CS, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16:1\u201316.","journal-title":"Breast Cancer Res"},{"key":"1539_CR23","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","volume":"23","author":"US Asghar","year":"2017","unstructured":"Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23:5561\u201372.","journal-title":"Clin Cancer Res"},{"key":"1539_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12957-020-01907-7","volume":"18","author":"L Xia","year":"2020","unstructured":"Xia L, Hu Q, Zhang J, et al. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases. World J Surg Oncol. 2020;18:129. https:\/\/doi.org\/10.1186\/s12957-020-01907-7.","journal-title":"World J Surg Oncol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-021-01539-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T12:03:12Z","timestamp":1637841792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-021-01539-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1539"],"URL":"https:\/\/doi.org\/10.1186\/s12905-021-01539-3","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable for case reports at our institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"396"}}